Caribou Biosciences, Inc. is a pharmaceutical company based in the USA that focuses on using CRISPR technology to develop revolutionary genome-edited cell therapies. With an ESG score of 28.0, the company is considered to have medium risk. Caribou Biosciences is dedicated to transforming the lives of patients by leveraging their CRISPR hybrid RNA-DNA platform. Their main focus is on developing allogeneic CAR-T and CAR-NK cell therapies.